It can be said that Indonesian pharmaceutical industry is one of major reliable sectors for driving up the national economy. Amid the fluctuating condition of the country, this pharmaceutical sector is still able to grow positively, in fact higher than the national economic growth.

Based on data from Badan Pusat Statistik (BPS), the chemical, pharmaceutical and traditional medicine industry grew significantly by 7.38% in QII/2017, next to the metal industry. Based on these figures, PT. Visi Globalindo Data Utama predicts that the national pharmaceutical industry will grow by 6.33%-7.20% in the first quarter of 2018.

Regarding such astonishing performance of this industry, the government has committed to deepen the structure of this pharmaceutical industry, in order to lessen the dependency of the industry on the imported raw materials. It is a fact that the national pharmaceutical industry is still largely relying on the imported materials, as they have to use some 95% of raw materials from abroad.

Another challenge faced by this industry is the government medical insurance program (Program Jaminan Kesehatan Nasional), which factually only gives insignificant impact to the sales of pharmaceutical products. The reason is because this government program only covers certain segment of medicine products. Thus in the future, the industry expects the government to review this program policy and to apply regulations that can cover all segments of pharmaceutical products from this industry.

Author : Utari Palupi
Editor  : Utari Palupi